KNKiron Nair

Kiron Nair

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kiron Nair has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Jen Chin Wang

    Division of Hematology and Oncology, Brookdale University Hospital Medical Center, Brooklyn, NY, USA

    2 shared publications
  • Akriti Pokhrel

    Department of Hematology and Medical Oncology, Brookdale University Hospital Medical Center, One Brooklyn Health, Brooklyn, NY 11212, USA

    1 shared publication
  • Chi Chen

    Department of Food Science and Nutrition, University of Minnesota, St. Paul, MN, United States

    1 shared publication
  • Ching Wong

    Division of General Internal Medicine, University of California San Francisco, San Francisco, CA, United States

    1 shared publication
  • Gardith Joseph

    Division of Hematology and Oncology, Brookdale University Hospital and Medical Center, Brooklyn, NY

    1 shared publication
  • Guanfang Shi

    Division of Hematology and Oncology, Brookdale University Hospital and Medical Center, Brooklyn, NY

    1 shared publication

Latest Publications

  • Racial and ethnic differences in sickle cell disease within the United States: From demographics to outcomes

    by Akriti Pokhrel, Adeniran Olayemi, Stephanie Ogbonda, Kiron Nair, Jen Chin Wang

    Introduction: Sickle cell disease mainly affects African Americans, and studies on racial differences in sickle cell disease outcomes are scanty. This study examined racial and ethnic differences in sickle cell disease prevalence, comorbidities, and outcomes.Methods: Using the National Inpatient Sample database from 2016 to 2018, we identified patients' records with a diagnosis of sickle cell disease using the International Classification of Diseases, Tenth Revision codes. The overall study population was further stratified by race into Blacks, Whites, and Hispanics. Using logistic regression, comorbidities and outcomes among sickle cell disease patients were compared between the three races/ethnicities.Results: Of the 74 817 hospitalized for sickle cell disease, 69 889 (93.4%) were Blacks, 3603 (4.8%) were Hispanics, and 1325 (1.8%) were Whites. Compared to Whites, Blacks were more likely to have significantly higher odds of sickle cell crisis (odds ratio [OR]: 3.32; 95% confidence interval [CI]: 2.66–4.14) and blood transfusion (OR: 1.66; 95% CI: 1.37–2.02). There was no difference in mortality between Blacks and Whites. Compared to Hispanics, Blacks had significantly higher odds of sickle cell crisis (OR: 1.35; 95% CI: 1.19–1.53) and blindness (OR: 2.94; 95% CI: 1.22–7.11), lower odds of asplenia (OR: 0.57; 95% CI: 0.45–0.71) and gallstones (OR: 0.75; 95% CI: 0.58–0.95). However, Blacks had statistically significantly lower odds of mortality of 0.60 (95% CI: 0.38–0.93) than Hispanics.Conclusion: Prevalent sickle cell type, severity, complications, and comorbidities vary in different races. Physicians need to be aware of these differences to manage sickle cell patients efficiently. This study hopes to inform further research regarding the reasons for varying disease characteristics among racial groups and bridge a gap in tailored management protocols.


  • Open Access

    TLR, RAGE, and HMGB1 in the Inflammatory Response in Ph(-) Myeloproliferative Neoplasm

    by Guanfang Shi, Kiron Nair, Preethi Ramachandran, Chi Chen, Ching Wong, Gardith Joseph, Vladimir Gotlieb, Maksim Liaukovich, Jen-Chin Wang

    Recent evidence of increased constitutional symptoms and inflammatory cytokines in Philadelphia chromosome negative (Ph (-)) MPN suggests that an inflammatory response is important in the pathogenesis of Ph (-) MPN. Toll-like receptors (TLR), Receptor for Advanced Glycation End products (RAGE) and High mobility group protein B1 (HMGB1) are the important pathways for the inflammatory response. All these three important pathway proteins were studied in MPN diseases in the current studies. Materials and Methods: TLR assay. TLR 2,3, 4, 7, 9 quantification was performed by immuno-staining of 1×106 mononuclear cells (peripheral blood) which were incubated with fluorescence-conjugated anti-TLR-2,3, 4, 7, 9 antibodies and assayed by flow cytometry. HMGB1assay:HMGB1 ELISA kit from Immuno-Biological Laboratories, Inc. (IBL-America) were used. The plasma samples were diluted four times with the provided sample dilution buffer, and assayed in duplicate according to the manufacturer's suggestion. RAGE (RT-PCR) Assay: Total RNA was extracted from normal control or patient mononuclear cells. Predesigned primers for RAGE, and internal control genes were ordered from Qiagen (Germantown, MD). Real-time PCR was performed using SsoAdvanced™ Universal SYBR® Green Supermix (Bio-Rad, Hercules, CA) on Bio-Rad iQ5 Multicolor Real-Time PCR Detection System. At least three house-keeping genes (ribosomal protein L4, TATA box binding protein, and tubulin-α 1b) were used as normalization controls. The expression of RAGE were compared with each internal control. Average of three was used to calculate the ratio of final patient to normal Results: Total of 97 patients with MPN were studied 1) TLR: TLR 3,7,9 was not significantly different from controls. But TLR 2 was significantly increased in both PV, as well as in the MPN group when PV, ET and MF were grouped together as MPN (Fig A). TLR 4 was not significantly increased in PV, ET, MF individually but was found to be significantly increased than the controls, when they are grouped together as MPN (Fig B). 2) RAGE: No significant difference was found between ET, PV, MF individually or when they were grouped together as MPN than the controls (Fig C). 3) HMGB1: No significant difference was seen between ET, PV, MF or when they were grouped as MPN (Fig D). Conclusion: Current study suggests that TLR pathway especially TLR2, and to a lesser extent TLR4 are the important pathways for inflammatory response with increased inflammatory cytokines in MPN, while HMGB1 and RAGE pathways were not different from controls. Figure Disclosures No relevant conflicts of interest to declare.